Faron Pharmaceuticals Oy · LSE:FARN
Faron Pharmaceuticals Oy — Shareholder Meeting (May 2018)
24 slides from Faron Pharmaceuticals Oy's shareholder meeting presentation, May 31, 2018
Slide 1: Faron Pharmaceuticals (LSE: FARN) Annual General Meeting
Faron Pharmaceuticals (LSE: FARN) Annual General Meeting 31 May 2018 1
Slide 2: Disclaimer
DISCLAIMER The contents of this presentation have not been approved by an authorised person within the meaning of Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA"). Reliance on the contents of this presentation for the purpose of engaging in any investment activity may
Slide 3: We See Barriers as Opportunities
WE SEE BARRIERS AS OPPORTUNITIES Faron’s pipeline is based on endothelial receptors involved in regulation of immune responses and vascular dysfunctions Immuno-Oncology ARDS & Organ protection Clever-1 regulates CD73 controls capillary tissue immune status leakage and escalation of inflammation AOC3
Slide 4: Multi-Asset Pipeline Targeting Significant Unmet Medical Needs
MULTI-ASSET PIPELINE TARGETING SIGNIFICANT UNMET MEDICAL NEEDS 4
Slide 5: Annual Results 2017
ANNUAL RESULTS 2017
Slide 6: Key Operational Highlights
KEY OPERATIONAL HIGHLIGHTS (including Post Period-end) Traumakine INTEREST trial for moderate and severe ARDS did not meet primary endpoint Japanese partner Maruishi progressed pivotal trial aiming at completion in mid 2018 Second independent manufacturing facility established INFORAAA study
Slide 7: Key Financial & Corporate Highlights
KEY FINANCIAL & CORPORATE HIGHLIGHTS (including Post Period-end) Financial Raised £5m in March 2017, £10m in October 2017 and £15m in February 2018 Cash balance of €9.3m on 31 December 2017 Operating loss of €21.1m (2016: €10.1m) Net assets of €4.7m on 31 December 2017 Cash balance of €18.
Slide 8: Traumakine: Interferon-Beta Treatment of ARDS and Other Ischaemic Reperfusion Injuries
INTERFERON-BETA TREATMENT OF ARDS AND OTHER ISCHAEMIC REPERFUSION INJURIES TRAUMAKINE®
Slide 9: Acute Respiratory Distress Syndrome – Significant Opportunity
ACUTE RESPIRATORY DISTRESS SYNDROME – SIGNIFICANT OPPORTUNITY Orphan lung disease with no available drug treatment ARDS is a rare disease characterised by vascular leakage and inflammation of the lungs and acute but persistent loss of lung function Causes include: pneumonia (bacteria/virus), sepsis,
Slide 10: Compelling Phase I/II Trial Results
COMPELLING PHASE I/II TRIAL RESULTS Data published below comparable to Japanese clinical trial Reduction in ICU stay from 28 to 16 days, saving money and improving ICU capacity Primary endpoint: significant drop in mortality* Traumakine® treated (n=37, APACHE II of 22) Phase I/II trial showed a sign
Slide 11: The INTEREST Study Design
THE INTEREST STUDY DESIGN 30.5.2018 • A Phase III Double-blind, Randomised, Parallel-Group Comparison of the Efficacy INTEREST and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a, Traumakine) and Placebo in the Treatment of Patients with Moderate or Severe Acute Respiratory Distress Synd
Slide 12: Topline Results: Phase III INTEREST Study
TOPLINE RESULTS: PHASE III INTEREST STUDY INTEREST study did not meet the Day 28 (D28) primary composite endpoint of ventilator free days alive and all cause mortality with Traumakine treatment ➢ Treatment with Traumakine did not result in a reduced mortality rate, or an increased number of ventilat
Slide 13: Development Status for Traumakine in RAAA
DEVELOPMENT STATUS FOR TRAUMAKINE IN RAAA Trial to be paused pending further investigations into INTEREST outcome Ruptured Abdominal Aortic Aneurysm (RAAA) • Abdominal aortic aneurysm (AAA) is a potentially life-threatening condition that results from the degeneration of the arterial wall • The most
Slide 14: Novel Technologies to Control Immune Suppression: Clevegen
NOVEL TECHNOLOGIES TO CONTROL IMMUNE SUPPRESSION IN VARIOUS CONDITIONS CLEVEGEN®
Slide 15: Cancer Immunotherapy Based on Type II Macrophage (M2) Elimination
CANCER IMMUNOTHERAPY BASED ON TYPE II MACROPHAGE (M2) ELIMINATION Clevegen limits the function of tumour associated type II macrophages (M2 TAM), a known immunosuppressive cell group in tumours Circulation CURRENT LANDSCAPE Bone marrow Activation of T-cells (eACT), acquired by Stem cell Monocyte Act
Slide 16: Clevegen Mode of Action in Cancer Fight
CLEVEGEN® MODE OF ACTION IN CANCER FIGHT Footnotes 16
Slide 17: Macrophage Dependent Cancer Immunotherapy
MACROPHAGE DEPENDENT CANCER IMMUNOTHERAPY 17
Slide 18: Clevegen Value Drivers
CLEVEGEN VALUE DRIVERS Provides stand-alone or immune combination therapies to combat cancer Novel mode of action to remove immune suppression around tumours • Targets unique immune switch molecule Clever-1 on the surface of tumour associated type 2 macrophages (TAM-2) • No expected abnormalities fo
Slide 19: Clevegen Development Pathway
CLEVEGEN® DEVELOPMENT PATHWAY 1 2 3 4 5 Antibody GMP Protocol Research humani- Phase I/II Phase II production design sation Completed Completed In progress In progress 2017-2019 2019-2021 1 Excellent IP-coverage on Clever-1 target and function blocking antibodies The product is an anti-Clever-1 anti
Slide 20: Macrophage Clever-1, a New Immune Switch Molecule
MACROPHAGE CLEVER-1, A NEW IMMUNE SWITCH MOLECULE Clever-1 Targeting Provides Significant Technology and Business Opportunities Tumour Immunity Enabling • Removal of local immune suppression around tumours or in cancer Technology (TIET- patients programme) • Analysis of patient immune status from bl
Slide 21: Summary
Pharmaceuticals
Slide 22: Outlook and Upcoming News Flow
OUTLOOK AND UPCOMING NEWS FLOW Current focus on cash preservation and how best to create value for shareholders Traumakine Further analysis of the INTEREST trial data Top-line data from Phase III Japanese study in 2018 Further update on INFORAAA in 2018 Potentially a new commercial model for
Slide 23: Footnotes
= FARON Pharmaceuticals
Slide 24: Leadership Overview
LEADERSHIP OVERVIEW Experienced team building internal medical and business intelligence EXECUTIVE DIRECTORS Dr Markku Jalkanen, Chief Executive Officer & Founder • Over 25 years’ experience in biomedical research, biotech development and the biopharmaceutical industry • Former CEO of Biotie Therapi
Faron Pharmaceuticals Oy — Shareholder Meeting (May 2018) on 6ix